JP2024038127A5 - - Google Patents
Info
- Publication number
- JP2024038127A5 JP2024038127A5 JP2023219428A JP2023219428A JP2024038127A5 JP 2024038127 A5 JP2024038127 A5 JP 2024038127A5 JP 2023219428 A JP2023219428 A JP 2023219428A JP 2023219428 A JP2023219428 A JP 2023219428A JP 2024038127 A5 JP2024038127 A5 JP 2024038127A5
- Authority
- JP
- Japan
- Prior art keywords
- cbd
- formulation
- cannabidiol
- thc
- cannabinoids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806953.4A GB201806953D0 (en) | 2018-04-27 | 2018-04-27 | Cannabidiol Preparations |
| GB1806953.4 | 2018-04-27 | ||
| PCT/GB2019/051173 WO2019207319A1 (en) | 2018-04-27 | 2019-04-26 | Cannabidiol preparations and its uses |
| JP2020560164A JP7779656B2 (ja) | 2018-04-27 | 2019-04-26 | カンナビジオール製剤及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560164A Division JP7779656B2 (ja) | 2018-04-27 | 2019-04-26 | カンナビジオール製剤及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038127A JP2024038127A (ja) | 2024-03-19 |
| JP2024038127A5 true JP2024038127A5 (https=) | 2026-02-12 |
Family
ID=62494972
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560164A Active JP7779656B2 (ja) | 2018-04-27 | 2019-04-26 | カンナビジオール製剤及びその使用 |
| JP2023219428A Pending JP2024038127A (ja) | 2018-04-27 | 2023-12-26 | カンナビジオール製剤及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560164A Active JP7779656B2 (ja) | 2018-04-27 | 2019-04-26 | カンナビジオール製剤及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20210052512A1 (https=) |
| EP (2) | EP4509177A3 (https=) |
| JP (2) | JP7779656B2 (https=) |
| KR (1) | KR102822704B1 (https=) |
| CN (1) | CN112512585A (https=) |
| AU (1) | AU2019259230B2 (https=) |
| BR (1) | BR112020021884A2 (https=) |
| DK (1) | DK3784283T3 (https=) |
| EA (1) | EA202092582A1 (https=) |
| ES (1) | ES3000752T3 (https=) |
| FI (1) | FI3784283T3 (https=) |
| GB (2) | GB201806953D0 (https=) |
| IL (1) | IL278224B2 (https=) |
| MX (1) | MX2020011163A (https=) |
| WO (1) | WO2019207319A1 (https=) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| WO2020028198A1 (en) | 2018-08-03 | 2020-02-06 | Biomass Oil Separation Solutions, Llc | Processes and apparatus for extraction of substances and enriched extracts from plant material |
| GB2579179A (en) * | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB2580653A (en) * | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
| WO2020152336A1 (en) * | 2019-01-25 | 2020-07-30 | Universitat Autonoma De Barcelona | Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| GB2583526A (en) * | 2019-05-03 | 2020-11-04 | Gw Res Ltd | Use of cannabidiol in the treatment of tuberous sclerosis complex |
| GB2584140A (en) * | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| US10799546B1 (en) | 2019-07-26 | 2020-10-13 | Biomass Oil Separation Solutions, Llc | Modular, integrated process and apparatus for extracting, refining and remediating active substances from plant material |
| GB2586026A (en) * | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
| KR20220044558A (ko) * | 2019-08-05 | 2022-04-08 | 씨에스 메디카 에이/에스 | 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도 |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| AU2020358869A1 (en) | 2019-10-03 | 2022-04-14 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| EP4041209A4 (en) | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| GB2589306A (en) * | 2019-10-25 | 2021-06-02 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of fragile X syndrome |
| GB2588457B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
| GB2588456B (en) * | 2019-10-25 | 2023-02-01 | Gw Res Ltd | Cannabinoid compound |
| GB2588461A (en) * | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of absence epilepsy |
| GB2588460A (en) * | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of temporal lobe epilepsy |
| GB2588455B (en) * | 2019-10-25 | 2022-12-21 | Gw Res Ltd | Cannabinoid compound |
| GB201916846D0 (en) * | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB201916977D0 (en) * | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| GB2597319A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597283A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597312A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597305A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597284A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with multifocal epilepsy |
| GB2597314A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597303A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury |
| GB2597293A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597320A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597281A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury |
| GB2599340A (en) * | 2020-07-20 | 2022-04-06 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597306A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597304A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
| GB2597301A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with herpes simplex virus |
| GB2597297A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597321A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597322A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597279A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597282A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| WO2022017936A1 (en) * | 2020-07-20 | 2022-01-27 | GW Research Limited | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597280A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome |
| GB2597308A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597290A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597302A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage |
| GB2597316A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597310A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597299A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| GB2597285A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597313A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597291A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597318A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597309A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597315A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597298A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with brain damage |
| GB2597311A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597317A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597307A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with encephalitis |
| GB2597295A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol, in the treatment of seizures associated with rare epilepsy syndromes |
| GB2600077A (en) * | 2020-07-20 | 2022-04-27 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
| GB2597296A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury |
| GB202013765D0 (en) * | 2020-09-02 | 2020-10-14 | Gw Res Ltd | Method of preparing cannabinoids |
| WO2022103639A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| GB2601755A (en) * | 2020-12-08 | 2022-06-15 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes |
| GB2602019A (en) | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
| GB2606334A (en) * | 2021-02-12 | 2022-11-09 | Gw Res Ltd | Use of cannabidivarin in the treatment of seizures associated with canine epilepsy |
| CN113209162A (zh) * | 2021-05-19 | 2021-08-06 | 上海交通大学 | 大麻提取物的应用及包括大麻提取物的药物 |
| KR20240119247A (ko) * | 2021-09-01 | 2024-08-06 | 스핀아트, 엘엘씨 | 질 외음 및 항문 주위 조직 활력 및 조직 건강을 촉진 및/또는 유지하기 위한 조성물 및 방법 |
| EP4406934A4 (en) | 2021-09-15 | 2025-08-13 | Kangwon Univ Industry Cooperation Foundation | NOVEL CANABIDIOL DERIVATIVE, PREPARATION METHOD THEREOF AND COMPOSITION FOR IMPROVING COGNITIVE FUNCTIONS COMPRISING IT |
| CA3235074A1 (en) | 2021-10-26 | 2023-05-04 | Alexandra M CAPANO | Methods of treating ovarian cancer with hemp extract |
| AU2022376836A1 (en) | 2021-10-26 | 2024-05-23 | Dove Innovation Pty Limited | Methods of treating head and neck cancers with hemp extract |
| IL312245A (en) | 2021-10-26 | 2024-06-01 | Ecofibre Usa Inc | Methods of treating endometriosis and other non-cancerous gynecological disorders with hemp extract |
| EP4422769A2 (en) | 2021-10-26 | 2024-09-04 | Ecofibre USA Inc. | Systems and methods for producing hemp extracts and compositions |
| KR102634945B1 (ko) | 2021-11-16 | 2024-02-08 | (주)케이메디켐 | 신규한 카나비크로멘산 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물 |
| WO2023161921A2 (en) * | 2022-02-23 | 2023-08-31 | Cannabotech Ltd. | Compositions for use as an adjunctive therapy in the treatment of breast cancer |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US11911427B2 (en) | 2022-03-12 | 2024-02-27 | Wilhelm Rumpf | Extraction and infusion of active components from plant materials |
| CN115364050B (zh) * | 2022-08-02 | 2023-07-18 | 无锡诺平医药科技有限公司 | H2cbd乳液、制备方法及其药物应用 |
| AU2023321655A1 (en) | 2022-08-12 | 2025-02-13 | Jazz Pharmaceuticals Research Uk Limited | Oral solid dosage forms comprising cannabinoids |
| EP4608426A1 (en) | 2022-10-26 | 2025-09-03 | Ecofibre USA Inc. | Stabilized compositions comprising cannabidiol |
| IL320517A (en) | 2022-10-26 | 2025-06-01 | Ecofibre Usa Inc | Methods for treating estrogen-sensitive diseases with cannabis extract |
| GB2627344A (en) * | 2022-12-16 | 2024-08-21 | Kingdom Therapeutics Ltd | Cannabinoid based therapy |
| US12023346B1 (en) | 2023-07-24 | 2024-07-02 | Poviva Corp | Compositions and methods for treating epilepsy |
| US11931369B1 (en) | 2023-07-24 | 2024-03-19 | Poviva Corp | Compositions and methods for treating epilepsy |
| US11986485B1 (en) | 2023-07-24 | 2024-05-21 | Poviva Corp | Compositions and methods for treating epilepsy |
| US11944635B1 (en) | 2023-07-24 | 2024-04-02 | Poviva Corp | Compositions and methods for treating epilepsy |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2304669A (en) | 1940-08-16 | 1942-12-08 | Adams Roger | Isolation of cannabidiol |
| JPS5430146A (en) | 1977-08-05 | 1979-03-06 | Microbial Chem Res Found | Novel anthracycline derivatives and their preparation |
| GB9726916D0 (en) | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
| IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
| GB2381194A (en) | 2001-09-07 | 2003-04-30 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
| DK1361864T3 (en) | 2001-02-14 | 2014-03-03 | Gw Pharma Ltd | FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids |
| US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| GB2377633A (en) | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
| GB2377218A (en) | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
| ATE533472T1 (de) | 2002-08-14 | 2011-12-15 | Gw Pharma Ltd | Flüssige cannabinoid-formulierungen zur verabreichung an die schleimhäute |
| US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
| KR101113162B1 (ko) | 2002-08-14 | 2012-06-20 | 지더블유 파마 리미티드 | 식물물질로부터 약제학적 활성성분의 추출의 개량 |
| GB2393182B (en) | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
| KR20060040676A (ko) * | 2003-07-11 | 2006-05-10 | 미리어드 제네틱스, 인크. | 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형 |
| GB2414933B (en) * | 2004-06-08 | 2009-07-15 | Gw Pharma Ltd | Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis |
| WO2006017892A1 (en) | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| AU2005305675B2 (en) | 2004-11-16 | 2012-12-13 | Jazz Pharmaceuticals Operations Uk Limited | New use for cannabinoid |
| TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| GB2432312A (en) | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
| GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
| GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| WO2008019146A2 (en) | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| WO2008061160A1 (en) | 2006-11-14 | 2008-05-22 | Pharmacyclics, Inc. | Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
| GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
| DK2176208T3 (en) | 2007-07-30 | 2015-04-27 | Zynerba Pharmaceuticals Inc | Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof |
| GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| LT2280687T (lt) | 2008-03-26 | 2019-08-26 | Stichting Sanammad | Kramtomosios gumos kompozicijos, apimančios kanabinoidus |
| HUE032158T2 (en) | 2008-10-31 | 2017-09-28 | Univ Mississippi | Process for the preparation of delta9-THC amino acid esters |
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| US20110033529A1 (en) | 2009-08-06 | 2011-02-10 | Durga Prasad Samantaray | Oral pharmaceutical paricalcitol formulations |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| GB2487183B (en) | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
| WO2011156405A2 (en) | 2010-06-07 | 2011-12-15 | Novadel Pharma Inc. | Oral spray formulations and methods for administration of sildenafil |
| US8895537B2 (en) | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2491118B (en) | 2011-05-20 | 2015-12-30 | Otsuka Pharma Co Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US20150181924A1 (en) | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
| US9259449B2 (en) | 2014-01-07 | 2016-02-16 | Joshua Michael Raderman | Method for modifying THC content in a lipid-based extract of cannabis |
| WO2015142501A1 (en) | 2014-03-21 | 2015-09-24 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| EP4151234A1 (en) | 2014-05-29 | 2023-03-22 | Fresh Cut Development, LLC | Stable cannabinoid formulations |
| US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
| WO2015187988A1 (en) | 2014-06-04 | 2015-12-10 | Intellimedix | Composition and methods of treating epilepsy and/or epilepsy-related disorders |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| JP6676062B2 (ja) | 2014-11-03 | 2020-04-08 | ラモト アト テルーアビブ ユニバーシティー リミテッド | 認知低下を処置するための方法 |
| EP3226847A2 (en) | 2014-12-04 | 2017-10-11 | Servicio Andaluz De Salud | Use of cannabinoids as ceramide-generating anticancer agents in tumors of the hematopoietic and lymphoid tissues |
| MX395015B (es) | 2014-12-12 | 2025-03-24 | Ojai Energetics Pbc | Composiciones microencapsuladas de cannabinoides |
| SG10202012002TA (en) * | 2015-05-11 | 2021-01-28 | Lundbeck La Jolla Research Center Inc | Methods of treating inflammation or neuropathic pain |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2542155B (en) * | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| GB2548873B (en) * | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| IL248150B (en) | 2016-09-29 | 2018-05-31 | Garti Nissim | Method for selective extraction of cannabinoids from a plant source |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| EP3558297A1 (en) | 2016-12-20 | 2019-10-30 | Tilray, Inc. | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
| GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
| GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10751380B2 (en) | 2018-03-08 | 2020-08-25 | Alexander Kariman | Compound and method for treating spasms, inflammation and pain |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| GB2580881A (en) | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2018
- 2018-04-27 GB GBGB1806953.4A patent/GB201806953D0/en not_active Ceased
-
2019
- 2019-04-26 CN CN201980043260.8A patent/CN112512585A/zh active Pending
- 2019-04-26 US US17/050,956 patent/US20210052512A1/en not_active Abandoned
- 2019-04-26 AU AU2019259230A patent/AU2019259230B2/en active Active
- 2019-04-26 MX MX2020011163A patent/MX2020011163A/es unknown
- 2019-04-26 EA EA202092582A patent/EA202092582A1/ru unknown
- 2019-04-26 WO PCT/GB2019/051173 patent/WO2019207319A1/en not_active Ceased
- 2019-04-26 EP EP24207947.3A patent/EP4509177A3/en active Pending
- 2019-04-26 GB GB1905876.7A patent/GB2574321A/en not_active Withdrawn
- 2019-04-26 FI FIEP19721363.0T patent/FI3784283T3/fi active
- 2019-04-26 ES ES19721363T patent/ES3000752T3/es active Active
- 2019-04-26 DK DK19721363.0T patent/DK3784283T3/da active
- 2019-04-26 JP JP2020560164A patent/JP7779656B2/ja active Active
- 2019-04-26 IL IL278224A patent/IL278224B2/en unknown
- 2019-04-26 BR BR112020021884-7A patent/BR112020021884A2/pt unknown
- 2019-04-26 KR KR1020207033611A patent/KR102822704B1/ko active Active
- 2019-04-26 EP EP19721363.0A patent/EP3784283B1/en not_active Revoked
-
2020
- 2020-09-03 US US17/011,715 patent/US11207292B2/en active Active
-
2021
- 2021-11-17 US US17/529,005 patent/US11865102B2/en active Active
-
2023
- 2023-08-08 US US18/446,405 patent/US20240207220A1/en active Pending
- 2023-12-26 JP JP2023219428A patent/JP2024038127A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038127A5 (https=) | ||
| JP2021522261A5 (https=) | ||
| FI3784283T3 (fi) | Kannabidiolivalmisteita ja niiden käyttöjä | |
| FI3494119T3 (fi) | Yhdisteitä ja koostumuksia ja niiden käyttötapoja | |
| EA201991375A1 (ru) | Бицикло[1.1.1]пентановые ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| KR20180050407A (ko) | LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체 | |
| WO2019234728A1 (en) | Cannabinolic acid derivatives and uses thereof | |
| FI3723752T3 (fi) | Kannabidiolin uudet kiinteät olomuodot ja niiden käyttötarkoitukset | |
| TW200607823A (en) | Process for the production of very pure 2, 4'-methylenediphenyl diisocyanate | |
| CN110478343A (zh) | 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物 | |
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| MD3755684T2 (ro) | Derivați de alcool ca deschizători ai canalelor de potasiu Kv7 | |
| CN106928081A (zh) | 稠合环γ‑ 氨基酸衍生物及其制备方法和在医药上的应用 | |
| Sadarangani et al. | Synthesis, resolution and anticonvulsant activity of chiral N-1′-ethyl, N-3′-(1-phenylethyl)-(R, S)-2′ H, 3H, 5′ H-spiro-(2-benzofuran-1, 4′-imidazolidine)-2′, 3, 5′-trione diastereomers | |
| KR20130132829A (ko) | 인돌 유도체 및 이의 제조 방법 | |
| GB2588458A (en) | Cannabidivarin preparations | |
| WO2006067428A3 (en) | 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands | |
| AU2022399234A1 (en) | Analogues of mdma for modulating sert, dat, and / or net activity | |
| WO2007100583A2 (en) | Propargylated aminoindans, processes for preparation, and uses thereof | |
| CN111902143B (zh) | 神经细胞内钙浓度上升抑制剂 | |
| EP3490607A1 (en) | Compounds and compositions and uses thereof | |
| TW200635589A (en) | Therapeutic agents | |
| EP4519252A1 (en) | Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor | |
| Fernandes et al. | [2+ 2] Photocycloadditions with chiral uracil derivatives: access to all four stereoisomers of 2-aminocyclobutanecarboxylic acid | |
| CN101250131A (zh) | 对乙酰氨基苯酚的制备工艺 |